Silvana Battaglia, Executive Vice President at Cencora, Inc. (NYSE:COR), recently sold 1,678 shares of the company's common stock. The healthcare services giant, with a market capitalization of $44 billion, has demonstrated strong financial health according to InvestingPro analysis, maintaining a 20-year track record of consecutive dividend increases. The transaction, which took place on December 20, involved shares sold at an average price of $228.72 each, totaling approximately $383,792. According to InvestingPro analysis, the stock appears undervalued at current levels, with 14 additional exclusive insights available to subscribers. Following this sale, Battaglia retains ownership of 20,329 shares in the company. Cencora, formerly known as AmerisourceBergen (NYSE:COR) Corp, is headquartered in Conshohocken, Pennsylvania.
In other recent news, Cencora Inc. has reported robust growth in its fiscal 2024 fourth quarter, with earnings and revenue increasing by 15% year-over-year. Adjusted diluted EPS for Q4 rose by 17% to $3.34, and consolidated revenue reached $79.1 billion. The company also announced the acquisition of Retina Consultants of America (RCA), expected to add approximately $0.35 to earnings in its first year.
Mizuho (NYSE:MFG) has set an Outperform rating for Cencora, with a $280 target, based on a 16 times price-to-earnings (P/E) multiple of the projected calendar year 2026 earnings per share (EPS) of $17.00. This forecast is slightly above the consensus estimate of $16.62 EPS. In parallel, BofA Securities revised its stock price target for Cencora to $260, following Cencora's inaugural virtual Product Showcase event.
These are recent developments reflecting Cencora's strategic focus on specialty pharmaceuticals and infrastructure investments. The company's fiscal 2025 guidance projects an adjusted diluted EPS between $14.80 and $15.10 and a revenue growth of 7% to 9%. The company's relationship with its largest customer, Walgreens, is expected to remain stable, with potential for minor prescription volume and price reductions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.